We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.34B
AUM Growth
+$140M
Cap. Flow
+$87.9M
Cap. Flow %
3.75%
Top 10 Hldgs %
23.56%
Holding
168
New
20
Increased
60
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$65.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$38.6M
3
HCA icon
HCA Healthcare
HCA
+$36.9M
4
COR icon
Cencora
COR
+$28.3M
5
DVA icon
DaVita
DVA
+$24M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$67.4M
2
CI icon
Cigna
CI
+$65.2M
3
MRK icon
Merck
MRK
+$47.9M
4
JNJ icon
Johnson & Johnson
JNJ
+$27.9M
5
WTW icon
Willis Towers Watson
WTW
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.66%
2 Financials 1.72%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
101
DELISTED
La Jolla Pharmaceutical Company
LJPC
$6.55M 0.28%
+220,000
New +$7.09M
CBAY
102
DELISTED
Cymabay Therapeutics
CBAY
$6.37M 0.27%
490,000
+40,000
+9% +$497K
ZLAB icon
103
Zai Lab
ZLAB
$2.62B
$6.3M 0.27%
295,000
– –
ONCT
104
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$6.28M 0.27%
+2,529
New +$5.63M
MYOV
105
DELISTED
Myovant Sciences Ltd.
MYOV
$6.28M 0.27%
295,100
– –
MNTA
106
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$6.26M 0.27%
+345,000
New +$5.75M
ECYT
107
DELISTED
Endocyte, Inc. Common Stock
ECYT
$6.14M 0.26%
+675,000
New +$3.72M
A icon
108
Agilent Technologies
A
$41.2B
$6.12M 0.26%
+91,500
New +$6.41M
PRTK
109
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.85M 0.25%
450,000
– –
MRTX
110
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.8M 0.25%
189,000
+9,000
+5% +$250K
NVAX icon
111
Novavax
NVAX
$1.31B
$5.78M 0.25%
137,500
+37,500
+38% +$1.51M
TXMD icon
112
TherapeuticsMD
TXMD
$24M
$5.71M 0.24%
23,456
-44
-0.2% -$12.3K
SHPG
113
DELISTED
Shire pic
SHPG
$5.6M 0.24%
+37,500
New +$5.16M
CMTA
114
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$5.23M 0.22%
345,000
– –
ADVM
115
DELISTED
Adverum Biotechnologies
ADVM
$5.22M 0.22%
+90,000
New +$5.6M
SYRE icon
116
Spyre Therapeutics
SYRE
$9.25B
$5.2M 0.22%
20,964
– –
AIMT
117
DELISTED
Aimmune Therapeutics
AIMT
$5.09M 0.22%
160,000
-133,000
-45% -$4.68M
DVAX
118
DELISTED
Dynavax Technologies
DVAX
$4.98M 0.21%
251,000
+76,000
+43% +$1.31M
PRTA icon
119
CALL
Prothena Corp
PRTA
$450M
$4.96M 0.21%
135,000
+110,000
+440% +$4M
DERM
120
DELISTED
Dermira, Inc.
DERM
$4.79M 0.2%
600,000
+180,000
+43% +$3.92M
BCRX icon
121
BioCryst Pharmaceuticals
BCRX
$2.4B
$4.41M 0.19%
925,000
+112,500
+14% +$578K
ITCI
122
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.95M 0.17%
187,500
– –
EXEL icon
123
Exelixis
EXEL
$13.4B
$3.88M 0.17%
175,000
– –
CGEN icon
124
Compugen
CGEN
$228M
$3.67M 0.16%
825,000
– –
MRUS
125
DELISTED
Merus
MRUS
$3.24M 0.14%
174,917
-97,035
-36% -$1.76M
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rock Springs Capital Management held 168 positions worth $2.34B, up 6.4% from $2.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $87.9M of net new capital in Q1 2018, opening 20 new positions and adding to 60 existing holdings. Its largest new stake was AbbVie: 600,000 shares worth $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was PRA Health Sciences, Inc., an estimated $7.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2018 buy was AbbVie: 600,000 shares worth $56.8M.
  • Rock Springs Capital Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $38.6M increase.
  • Rock Springs Capital Management's biggest Q1 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $7.33M.
  • Rock Springs Capital Management fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $67.4M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $2.34B portfolio in Q1 2018.
  • Rock Springs Capital Management opened 20 new positions and closed 19 in Q1 2018.
  • Rock Springs Capital Management's portfolio value rose 6.4% quarter-over-quarter to $2.34B.

Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.